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Abstract
Objective. Develop a risk index to estimate the like-
lihood of life-threatening respiratory depression or
overdose among medical users of prescription
opioids.
Subjects, Design, and Methods. A case-control
analysis of administrative health care data from the
Veterans’ Health Administration identified 1,877,841
patients with a pharmacy record for an opioid pre-
scription between October 1, 2010 and September
30, 2012. Overdose or serious opioid-induced respi-
ratory depression (OSORD) occurred in 817. Ten
controls were selected per case (n5 8,170). Items for
an OSORD risk index (RIOSORD) were selected
through logistic regression modeling, with point val-
ues assigned to each predictor. Modeling of risk
index scores produced predicted probabilities of
OSORD; risk classes were defined by the predicted
probability distribution.
Results. Fifteen variables most highly associated
with OSORD were retained as items, including men-
tal health disorders and pharmacotherapy; impaired
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drug metabolism or excretion; pulmonary disorders;
specific opioid characteristics; and recent hospital
visits. The average predicted probability of experi-
encing OSORD ranged from 3% in the lowest risk
decile to 94% in the highest, with excellent agree-
ment between predicted and observed incidence
across risk classes. The model’s C-statistic was 0.88
and Hosmer–Lemeshow goodness-of-fit statistic
10.8 (P>0.05).
Conclusion. RIOSORD performed well in identifying
medical users of prescription opioids within the Vet-
erans’ Health Administration at elevated risk of over-
dose or life-threatening respiratory depression,
those most likely to benefit from preventive interven-
tions. This novel, clinically practical, risk index is
intended to provide clinical decision support for
safer pain management. It should be assessed, and
refined as necessary, in a more generalizable popula-
tion, and prospectively evaluated.
Key Words. Opioid; Risk; Respiratory Depression;
Overdose; Questionnaire; Index
Introduction
Unintentional opioid-related overdose in the United
States is an increasingly common yet preventable cause
of death among medical users of prescription opioids
[1,2]. Identifying risk factors and individuals at elevated
risk is a public health imperative and necessary to
implement effective preventive measures.
Serious toxicity and overdose events from prescription
opioid use have risen in the United States over the last two
decades and parallel a striking increase in opioid prescrib-
ing to manage acute and chronic pain [3–9]. The marked
increase in opioid prescribing overall is reflected in the U.S.
Veterans’ Health Administration (VHA), with the percentage
of all VHA patients receiving opioids growing from 18.9%
in Fiscal Year 2004 to 33.4% in Fiscal Year 2014 [10].
Opioids depress the central nervous system (CNS),
which may result in profound and potentially fatal respi-
ratory depression, sedation, and coma [11–13]. Pre-
scription opioid-related deaths in the United States have
almost quadrupled since 1999, to 16,917 in 2011, with
approximately 80% of fatal opioid-related overdoses
classified as unintentional [3]. More than half of overdo-
ses occur in patients who are prescribed a relatively
high morphine equivalent dose (MED) of >100 mg/day
or who misuse opioid analgesics [4]. However, patients
using opioids with daily MED as low as 20–50 mg can
experience unintentional life-threatening respiratory or
CNS depression under conditions that enhance these
effects or result in opioid accumulation or excessive
duration of action [14–17]. Certain pre-existing condi-
tions (e.g., liver, kidney, or pulmonary disease) or con-
comitant use of other medications or substances (e.g.,
sedative-hypnotics or alcohol) can negatively impact a
patient’s ability to tolerate opioid exposure, resulting in
overdose and serious respiratory/CNS depression.
Predictive models and scoring systems (risk indices)
that estimate the level of risk of an adverse outcome are
commonly developed in medical research and clinical
practice with the goal of preventing or mitigating an out-
come [18]. Examples include risk of suicidality [19], car-
diovascular disease [20–22], postoperative pulmonary
complications [23,24], and mortality [25].
Several screening instruments assess the risk of aber-
rant drug-related behaviors (misuse, abuse, or addiction)
in prescription opioid-treated patients, such as the
Opioid Risk Tool [26], Screener and Opioid Assessment
for Patients with Pain-Revised (SOAPP-R) [27], Pain
Medication Questionnaire (PMQ) [28], CAGE-Adapted to
Include Drugs (CAGE-AID) [29], Screening Tool for
Addiction Risk (STAR) [30], and the Screening Instru-
ment for Substance Abuse Potential (SISAP) [31]. How-
ever, no published instruments currently provide
clinically useful, evidence-based risk information about
the likelihood of opioid-induced overdose or life-
threatening respiratory/CNS depression [32].
We previously examined potential predictors of serious
prescription opioid-induced toxicity and overdose in a
case-control study of US military veterans [15]. Factors
with the most significant positive associations included
maximum prescribed daily MED 100 mg (with a signifi-
cant dose-response effect beginning at 20 mg), his-
tory of opioid dependence, hospitalization during the 6
months before the serious respiratory depression or
overdose event, liver disease, and use of extended-
release or long-acting opioids. Based on results from
the previous study, a practical risk index was developed
to estimate the likelihood of overdose or serious opioid-
induced respiratory depression (OSORD) among medi-
cal users of prescription opioids.
Methods
Study Design and Setting
The risk index was developed using a retrospective,
case-control analysis of administrative health care data
derived from VHA Medical SAS Inpatient and Outpatient
and VHA Decision Support databases. These include
information from all VHA Medical Centers and Outpa-
tient Clinics. The Western Institutional Review Board
determined that this study was exempt from full IRB
review.
Study Participants
This study used the same VHA population as our previ-
ous study that identified factors associated with pre-
scription opioid-induced respiratory depression or
overdose [15]. A total of 10,131,467 patients was
included in the VHA Medical SAS datasets from Octo-
ber 1, 2010 through September 30, 2012; of these,
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Table 1 Baseline descriptive characteristics of the study sample
Characteristics Cases (n5 817) Controls (n5 8,170)
n (%) n (%) P Value
DEMOGRAPHICS
Age (years), median (IQR) 62 (10) 62 (16) <0.001
Age Group (years)
18–34 27 (3.3) 565 (6.9) <0.001
35–44 31 (3.8) 619 (7.6)
45–54 115 (14.2) 1,240 (15.2)
55–64 377 (46.1) 2,672 (32.7)
651 267 (32.7) 3,074 (37.6)
Male 753 (92.2) 7,528 (92.1) 0.98
Race
Non-hispanic White 555 (67.9) 4,546 (55.6) <0.001
Non-hispanic Black 8 (10.2) 1,300 (15.9)
Hispanic 32 (3.9) 431 (5.3)
Other 147 (18) 1,893 (23.2)
Marital Status
Never married 102 (12.5) 1,227 (15) <0.001
Married 351 (43) 4,246 (52)
Separated 20 (2.5) 41 (0.5)
Divorced 285 (34.9) 2,268 (27.8)
Widowed 59 (7.2) 388 (4.8)
Body Mass Index (BMI, kg/m2)
Underweight (<18.5) 29 (3.6) 72 (0.9) <0.001
Normal (18.5–24.9) 193 (23.6) 1,197 (14.7)
Overweight (25.0–29.9) 224 (27.4) 2,070 (25.3)
Obese (30.0) 306 (37.5) 2,667 (32.6)
Missing 65 (8) 2,164 (26.5)
U.S. Census Region
Northeast 75 (9.2) 824 (10.1) <0.001
North Central 190 (23.3) 1,745 (21.4)
South 270 (33.1) 3,258 (39.9)
West 257 (31.5) 1,842 (22.6)
Other 25 (3.1) 501 (6.1)
CLINICAL CHARACTERISTICS
CCI score, mean (SD) 3.9 (3.3) 1.7 (2) <0.001
Individual CCI Comorbidities
Myocardial infarction 28 (3.4) 105 (1.3) <0.001
Congestive heart failure 93 (11.4) 308 (3.8) <0.001
Peripheral vascular disease 71 (8.7) 353 (4.3) <0.001
Cerebrovascular disease 57 (7) 343 (4.2) <0.001
Dementia 5 (0.6) 32 (0.4) 0.35
Chronic pulmonary disease 291 (35.6) 1,047 (12.8) <0.001
Rheumatologic disease (serious autoimmune) 6 (0.7) 96 (1.2) 0.26
Peptic ulcer disease 9 (1.1) 63 (0.8) 0.312
Mild liver disease 43 (5.3) 64 (0.8) <0.001
Diabetes 263 (32.2) 1,850 (22.6) <0.001
Hypertension 495 (60.6) 3,670 (44.9) <0.001
Depression 357 (43.7) 1,562 (19.1) <0.001
Use of warfarin 78 (9.6) 387 (4.7) <0.001
Hemiplegia or paraplegia 13 (1.6) 34 (0.4) <0.001
Renal disease 112 (13.7) 428 (5.2) <0.001
Any malignancy, including leukemia and lymphoma 147 (18) 646 (8) <0.001
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Table 1 Continued
Characteristics Cases (n5 817) Controls (n5 8,170)
n (%) n (%) P Value
Diabetes with chronic complications 92 (11.3) 432 (5.3) <0.001
Skin ulcers 122 (14.9) 302 (3.7) <0.001
Moderate or severe liver disease 28 (3.4) 19 (0.2) <0.001
Metastatic solid tumor 46 (5.6) 59 (0.7) <0.001
HIV/AIDS 11 (1.4) 42 (0.5) 0.003
Other Selected Comorbidities
Non-pain-related
Substance abuse and nonopioid substance dependence 215 (26.3) 764 (9.4) <0.001
Opioid dependence 105 (12.9) 97 (1.2) <0.001
Endocarditis 1 (0.1) 9 (0.1) 0.92
Viral hepatitis 106 (13) 249 (3) <0.001
Alcoholic hepatitis 3 (0.4) 5 (0.1) 0.005
Non-malignant pancreatic disease 24 (2.9) 49 (0.6) <0.001
Sexually transmitted disease 12 (1.5) 69 (0.8) 0.07
Herpes simplex 7 (0.9) 45 (0.6) 0.27
Skin infections/abscesses 85 (10.4) 286 (3.5) <0.001
Sleep apnea 147 (18) 652 (8) <0.001
Tobacco use disorder 301 (36.8) 1,266 (15.5) <0.001
PTSD 221 (27.1) 1,119 (13.7) <0.001
Bipolar disorder 86 (10.5) 239 (2.9) <0.001
ADHD 7 (0.9) 58 (0.7) 0.64
Schizophrenia 36 (4.4) 114 (1.4) <0.001
Anxiety disorder 180 (22) 681 (8.3) <0.001
OCD 5 (0.6) 19 (0.2) 0.045
Cardiovascular disease 172 (21.1) 764 (9.4) <0.001
Obesity 150 (18.4) 1,072 (13.1) <0.001
Pain-related
Low back disorders 380 (46.5) 2,099 (25.7) <0.001
Other back/neck disorders 214 (26.2) 1,048 (12.8) <0.001
Neuropathic disorder 170 (20.8) 717 (8.8) <0.001
Fibromyalgia 34 (4.2) 157 (1.9) <0.001
Chronic headache 88 (10.8) 427 (5.2) <0.001
Burns 4 (0.5) 16 (0.2) 0.089
Active traumatic injury 212 (26) 869 (10.6) <0.001
Motor vehicle accident 7 (0.9) 14 (0.2) <0.001
PRESCRIPTION DRUG INFORMATION
Opioid use 693 (84.8) 4,936 (60.4) <0.001
BY ACTIVE INGREDIENT
Hydrocodone 314 (38.4) 2,633 (32.2) <0.001
Oxycodone 305 (37.3) 876 (10.7) <0.001
Morphine 251 (30.7) 334 (4.1) <0.001
Tramadol 114 (14) 1,428 (17.5) 0.01
Methadone 107 (13.1) 139 (1.7) <0.001
Codeine 63 (7.7) 561 (6.9) 0.365
Fentanyl 49 (6) 44 (0.5) <0.001
Hydromorphone 38 (4.7) 28 (0.3) <0.001
Oxymorphone 1 (0.1) 1 (0) 0.04
Buprenorphine 0 (0) 2 (0) 0.66
Other* 2 (0.2) 4 (0.1) 0.04
BY FORMULATION
Extended-Release/Long-Acting (ER/LA) 369 (45.2) 499 (6.1) <0.001
Not ER/LA 633 (77.5) 4,807 (58.5) <0.001
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1,877,841 (18.5%) had at least one pharmacy record
for an opioid. Only patients with complete demographic
information on age, sex, and self-identified race, and
continuous medical and pharmacy benefits for the 6-
month baseline period before the index date were eligi-
ble for inclusion in the study. Cases were patients who
experienced OSORD (index event), as defined by the
International Classification of Disease, 9th Revision, Clin-
ical Modification (ICD-9-CM) and Current Procedure
Terminology (CPT) coding algorithm developed in our
prior work [15]. To optimize statistical power, 10 control
patients from those dispensed an opioid by VHA during
the study period were randomly selected per case and
assigned the same index date [33–35]. After eligibility
criteria were applied, 8,987 patients were included in
the present analysis (817 cases, 8,170 controls).
Variables
The outcome variable, OSORD, was defined by ICD diag-
nostic and CPT procedural codes [15]. Independent varia-
bles (Table 1) included demographics; the Charlson
Comorbidity Index (CCI) score [36–38]; individual CCI
comorbidities; other selected pain- and nonpain-related
comorbidities [39–42]; prescription medication information,
including opioid active ingredient, formulation, and MED
[43,44], and select concomitant medications known to
potentiate opioid effects; and health care utilization [15].
Table 1 Continued
Characteristics Cases (n5 817) Controls (n5 8,170)
n (%) n (%) P Value
Proportion of opioids5ER/LA† 0.25 (0.3) <0.1 (0.2) <0.001
BY ROUTE
Oral 692 (84.7) 4,923 (60.3) <0.001
Parenteral 6 (0.7) 6 (0.1) <0.001
Transdermal 48 (5.9) 44 (0.5) <0.001
NUMBER OF OPIOID PRESCRIPTIONS DISPENSED, Mean (SD) 6.8 (5.9) 2.5 (3.4) <0.001
NUMBER OF UNIQUE OPIOID NDCs, Mean (SD) 2.4 (1.9) 0.9 (1.1) <0.001
MAXIMUM PRESCRIBED DAILY MED (mg), Mean (SD) 98.7 (122.1) 24.2 (48.4) <0.001
Maximum Prescribed Daily MED Group
1–<20 35 (4.3) 1,331 (16.3) <0.001
20–<50 227 (27.8) 2,614 (32)
50–<100 163 (20) 718 (8.8)
100 268 (32.8) 273 (3.3)
Selected Nonopioid Drugs 747 (91.4) 5,905 (72.3) <0.001
Benzodiazepines 336 (41.1) 1,242 (15.2) <0.001
Antidepressants 565 (69.2) 2,886 (35.3) <0.001
Nonopioid analgesics 556 (68.1) 4,598 (56.3) <0.001
Muscle relaxants 226 (27.7) 1,288 (15.8) <0.001
Other Sedatives 125 (15.3) 609 (7.5) <0.001
Antipsychotics 239 (29.3) 772 (9.5) <0.001
Stimulants 14 (1.7) 51 (0.6) <0.001
ALL CAUSE HEALTH CARE UTILIZATION
Days of hospitalization, mean (SD) 9.6 (22.9) 1.1 (8) <0.001
Patients with 1 outpatient ED Visit 534 (65.4) 1,740 (21.3) <0.001
Patients with 1 outpatient office visit 792 (96.9) 7,333 (89.8) <0.001
Patients with 1 hospitalization 396 (48.5) 739 (9.1) <0.001
Patients with 1 prescription fill 800 (97.9) 7,561 (92.6) <0.001
Outpatient ED visits per patient, mean (SD) 2 (2.6) 0.4 (1) <0.001
Outpatient office visits per patient, mean (SD) 23 (18.6) 9.8 (11.3) <0.001
Hospitalizations per patient, mean (SD) 1 (1.5) 0.1 (0.5) <0.001
Pharmacy visits per patient, mean (SD) 24.6 (15) 12.9 (10.4) <0.001
* Other opioids included meperidine and pentazocine/naloxone.
† Proportion of opioid prescriptions dispensed to a patient during baseline that contained an extended-release/long-acting formu-
lation. Methadone is a long-acting opioid.
Abbreviations: CCI5Charlson Comorbidity Index; ED5emergency department; ER5extended-release; LA=long acting;
MED5morphine equivalent dose; NDC5National Drug Code.
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Data Analysis
Univariate statistics were calculated to characterize the
sample. Analyses of variance, t-tests, and Wilcoxon
Rank Sum tests, as appropriate, were used to compare
continuous variables between cases and controls, while
Chi-square tests were used to compare proportions of
categorical variables between cases and controls.
Multivariable logistic regression was conducted to
examine potential predictors of serious opioid-induced
respiratory depression or overdose. All independent vari-
ables with P< 0.25 on bivariate testing were initially
included in the model (Table 1). Variables with P> 0.10
were dropped from the model sequentially unless they
were identified as confounders (i.e., variables that, when
dropped from the model, resulted in a 20% or greater
change in parameter estimates for one or more of the
other variables, when compared with the original
model). The final model included confounders and all
variables with P 0.10. All statistical analyses were con-
ducted in SAS v9.3. (SAS, Cary, NC).
Risk Index Construction
Items for the risk index were selected from the model vari-
ables statistically significantly associated with OSORD.
The authors balanced the scientific and statistical robust-
ness of each variable’s association with opioid overdose
with the practical need for a relatively brief instrument
with simplified administration by health care personnel in
a busy community health care setting. Considerations
included: 1) statistical strength of association in this sam-
ple; 2) confirmation in the published literature that the
variable is a risk factor; 3) likely generalizability of the vari-
able to the U.S. population of medical users of prescrip-
tion opioids; and 4) feasibility of obtaining readily
available, valid information for all index items.
Point values were assigned to questionnaire items by
multiplying the regression-generated b coefficients by 10
and rounding to the nearest integer. For each patient, val-
ues were summed, yielding a risk index score [23,45].
The risk index scores were then used in a multiple logistic
regression model with life-threatening opioid-induced
respiratory depression or overdose as the outcome, to
produce predicted probabilities of the outcome [23,45]. A
power transformation (ln [risk index score125], with ln
indicating natural logarithm) reduced the skewness of the
risk index scores and improved model calibration [23,45].
Model performance was assessed with the Hosmer–
Lemeshow test for overall model goodness-of-fit and
receiver operating curves and corresponding C-statistics
for model discrimination between those with and with-
out the outcome of interest. Accepted C-statistic cutoffs
for reasonable and strong discrimination are 0.7 and
0.8, respectively [46].
To test the validity of the risk index, the distribution of
predicted probabilities was compared by deciles to that
of the observed occurrence of serious toxicity or over-
dose. Patient count, average predicted probability of the
outcome, and observed incidence of events were com-
puted for each risk class.
Results
Descriptive Statistics
Baseline sample characteristics, including demographics,
comorbidities, prescription medications, and health care
utilization, are in Table 1. As described in Zedler et al.,
unadjusted analyses showed that cases were significantly
more likely to be non-Hispanic; white; divorced, separated
or widowed; and to have received care in the southern or
western United States [15]. Cases also had a greater bur-
den of illness as indicated by a higher mean CCI score
and frequencies of most individual CCI and selected other
comorbidities. Several opioid-related factors were signifi-
cantly associated with OSORD, including opioid formula-
tion, route of administration, maximum prescribed daily
MED, and receipt of more opioid prescriptions overall.
Cases were prescribed other potentially interacting medi-
cations more frequently and had greater baseline health
care utilization than did controls [15].
Multivariable Modeling
Independent variables excluded from multivariable regres-
sion modeling due to P>0.25 on bivariate analysis
included dementia, peptic ulcer disease, endocarditis,
herpes simplex infection, attention deficit hyperactivity dis-
order, and buprenorphine or codeine prescription. Demo-
graphic variables associated with higher odds of OSORD
included age groups 45–54 years and 55, race/ethnicity
non-Hispanic white, and marital status never married or
widowed. Multiple CCI comorbidities were associated
with an event, with liver disease reflecting cirrhosis and
chronic hepatitis having the highest odds, followed by
skin ulcers, metastatic solid tumor, renal disease, and
chronic pulmonary disease. Opioid dependence1 was the
nonpain-related comorbidity with the highest likelihood
(OR 4.54, 95% CI 3.12, 6.63), followed by nonmalignant
pancreatic disease (OR 2.13, 95% CI 1.06, 4.25), a com-
bined variable of bipolar disorder or schizophrenia (OR
1.95, 95% CI 1.43, 2.67), and sleep apnea (OR 1.34,
95% CI 1.03, 1.75). Active traumatic injury was the only
pain-related comorbidity associated with higher odds of
the outcome (OR 1.48, 95% CI 1.18, 1.87) (Table 2).
Certain medication and health care utilization variables
were significantly associated with serious opioid-induced
respiratory depression or overdose. Maximum prescribed
daily MED 100 mg/day had the highest likelihood (OR
4.96, CI 3.24, 7.61), but MED levels 20 mg/day were
monotonically associated with increased probability of an
1In the International Classification of Disease, 9th and 10th
Revisions, substance “dependence” replaced “addiction with or
without tolerance.” We classified substance use disorders as
“opioid dependence” (304.0x, 304.7x) or “nonopioid substance
dependence and nondependent substance abuse.”
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Table 2 Multivariable logistic regression: Factors associated with serious opioid-induced respiratory
depression or overdose*
Covariate
All Patients
(Cases, n5 817; Controls, n5 8,170)
Odds Ratio 95% CI P Value
DEMOGRAPHICS
Age group (in years)†
18–34 (reference)
35–44 1.24 0.65 2.35 0.52
45–54 1.97 1.15 3.37 0.013
551 2.57 1.55 4.26 <0.001
Race/ethnicity
Non-Hispanic black (reference)
Non-Hispanic white 1.71 1.27 2.31 <0.001
Hispanic 1.53 0.9 2.59 0.12
Other 1.56 1.1 2.2 0.013
Marital status‡
Married (reference)
Separated/divorced 1.16 0.94 1.44 0.16
Never married 1.48 1.11 1.97 0.008
Widowed 2.12 1.46 3.08 <0.001
Geographic region
Northeast (reference)
North Central 1.29 0.91 1.84 0.16
South 1.13 0.81 1.58 0.48
West 1.56 1.11 2.2 0.01
Other 0.63 0.36 1.11 0.11
CLINICAL CHARACTERISTICS
Individual Charlson Index (CCI) comorbidities
Congestive heart failure 1.05 0.64 1.72 0.85
Peripheral vascular disease 1.14 0.78 1.67 0.50
Cerebrovascular disease 0.66 0.41 1.06 0.09
Chronic pulmonary disease 1.57 1.27 1.94 <0.001
Rheumatologic disease (serious autoimmune) 0.32 0.12 0.89 0.03
Mild liver disease 2.42 1.39 4.19 0.002
Use of warfarin 1.27 0.91 1.79 0.16
Renal disease 1.59 1.17 2.17 0.004
Any malignancy, including leukemia and lymphoma 1.28 0.95 1.72 0.10
Skin ulcers 2.31 1.48 3.61 <0.001
Metastatic solid tumor 1.88 1.04 3.41 0.04
Other selected comorbidities:
Non-pain-related
Opioid dependence 4.54 3.12 6.63 <0.001
Non-malignant pancreatic disease 2.13 1.06 4.25 0.03
Skin infections/abscesses 0.46 0.28 0.76 0.002
Sleep apnea 1.34 1.03 1.75 0.03
Bipolar disorder/schizophrenia§ 1.95 1.43 2.67 <0.001
Cardiovascular disease 1.2 0.77 1.88 0.41
Pain-related
Headache/migraine 1.25 0.9 1.74 0.18
Traumatic injury 1.48 1.18 1.87 <0.001
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event. After accounting for MED, ER/LA opioids had the
highest odds (OR 2.48, 95% CI 1.27, 4.88), followed by
methadone (OR 2.42, 95% CI 1.61, 3.66) or oxycodone
(OR 1.32, 95% CI 1.03, 1.69) prescription, and concomi-
tant antidepressant (OR 1.98, 95% CI 1.63, 2.41) or ben-
zodiazepine prescription (OR 1.49, 95% CI 1.22, 1.83).
Additionally, prescription opioid users who visited an
emergency department (ED) (OR 2.88, 95% CI 2.34,
3.54) or were hospitalized for one or more days in the 6-
month baseline period (OR 2.2, 95% CI 1.76, 2.76) had
higher odds of OSORD (Table 2). Four variables included
in the model were associated with lower odds of experi-
encing an overdose event: serious autoimmune rheuma-
tologic disease, skin infections/abscesses, tramadol
prescription, and having filled at least one prescription at
VHA during the baseline period.
Table 2 Continued
Covariate
All Patients
(Cases, n5 817; Controls, n5 8,170)
Odds Ratio 95% CI P Value
PRESCRIPTION OPIOID USE
By active ingredient
Hydrocodone 0.87 0.7 1.08 0.21
Oxycodone 1.32 1.03 1.69 0.03
Morphine 1.28 0.77 2.14 0.35
Tramadol 0.69 0.52 0.92 0.01
Methadone 2.42 1.61 3.66 <0.001
Fentanyl 0.63 0.11 3.76 0.61
Hydromorphone 1.85 0.96 3.58 0.07
By formulation
Not ER/LA (reference)
Extended-release/long-acting (ER/LA) 2.48 1.27 4.88 0.01
Proportion of opioids5ER/LA 0.65 0.28 1.54 0.33
By route
Oral (reference)
Parenteral or transdermal 3.08 0.58 16.48 0.19
Maximum prescribed morphine equivalent dose (MED, mg/day)
1-<20 (reference)
20-<50 1.59 1.19 2.12 0.002
50–<100 2.51 1.73 3.63 <0.001
100 4.96 3.24 7.61 <0.001
NON-OPIOID PRESCRIPTION DRUG USE
Benzodiazepines 1.49 1.22 1.83 <0.001
Antidepressants 1.98 1.63 2.41 <0.001
ALL-CAUSE HEALTH CARE UTILIZATION
1 day of hospitalization 2.2 1.76 2.76 <0.001
1 ED Visit 2.88 2.34 3.54 <0.001
1 Prescription fill 0.48 0.28 0.85 0.01
Model performance
C-statistic5 0.89
Hosmer-Lemeshow goodness-of-fit statistic5 7.49 (P> 0.05)
* The multivariable logistic regression model presented includes all variables retained at a P value of <0.10 and all variables con-
sidered to be confounders. This model was used for review and selection of items to be included in RIOSORD.
† Age categories 55–64 and 651 were collapsed into one category, 551, for multivariable modeling.
‡ Marital status categories separated and divorced were collapsed into one category, separated/divorced, for multivariable
modeling.
§ The comorbidities bipolar disorder and schizophrenia were combined into one variable, bipolar disorder/schizophrenia, for multi-
variable modeling.
Abbreviations: CCI5Charlson Comorbidity Index; ED5 emergency department; ER5 extended release; LA5 long-acting;
MED5morphine equivalent dose; NDC5National Drug Code.
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The model had good discrimination and calibration, with
a C-statistic of 0.89 and Hosmer–Lemeshow goodness-
of-fit statistic of 7.49 (P>0.05) (Table 2).
Screening Risk Index
Table 3 shows the statistically significant predictors in the
final model that were retained as items in the risk index,
and their corresponding, assigned point values. Table 4
presents risk classes by deciles of predicted probability
and the corresponding observed incidence of OSORD
and risk scores. Based on risk factors present/absent
during the 6 months before the index event, the average
predicted probability of an event ranged from 3% in the
lowest risk class to 94% in the highest, and the observed
occurrence of an event increased commensurately.
The risk class model’s C-statistic was 0.88 and Hosmer–
Lemeshow goodness-of-fit statistic 10.8 (P> 0.05), indi-
cating very good calibration and discrimination between
patients with and without an event (Table 4).
Discussion
A novel screening tool was developed to estimate the risk
of overdose or life-threatening respiratory depression in
medical users of prescription opioids. The risk index for
overdose or serious opioid-induced respiratory depres-
sion (RIOSORD) performed well in the VHA study sample
in identifying patients at increased risk of such events.
Higher risk scores correlated closely with increased
observed occurrence of events. RIOSORD is the first
Table 3 Risk index for overdose or serious opioid-induced respiratory depression (RIOSORD)*
Question
Points for Yes
Response
In the past 6 months, has the patient had a healthcare visit (outpatient, inpatient or ED)
involving any of the following health conditions?†
Opioid dependence?‡ 15
Chronic hepatitis or cirrhosis? 9
Bipolar disorder or schizophrenia? 7
Chronic pulmonary disease (e.g., emphysema, chronic bronchitis, asthma, pneumoconiosis,
asbestosis)?
5
Chronic kidney disease with clinically significant renal impairment? 5
An active traumatic injury, excluding burns (e.g., fracture, dislocation, contusion, laceration,
wound)?
4
Sleep apnea? 3
Does the patient consume:
An extended-release or long-acting (ER/LA) formulation of any prescription opioid?§ (e.g.,
OxyContin, Oramorph-SR, methadone, fentanyl patch)
9
Methadone? (Methadone is a long-acting opioid so also check “ER/LA formulation” [9
points])
9
Oxycodone? (If it has an ER/LA formulation [e.g., OxyContin] also check “ER/LA for-
mulation” [9 points])
3
A prescription antidepressant? (e.g., fluoxetine, citalopram, venlafaxine, amitriptyline) 7
A prescription benzodiazepine? (e.g., diazepam, alprazolam) 4
Is the patient’s current maximum prescribed opioid dose#:
100 mg morphine equivalents per day? 16
50–<100 mg morphine equivalents per day? 9
20–<50 mg morphine equivalents per day? 5
In the past 6 months, has the patient:
Had one or more emergency department (ED) visits? 11
Been hospitalized for one or more days? 8
Total point score (maximum 115)
* This risk index is intended for completion by a health care professional.
† The condition does not have to be the primary reason for the visit but should be entered in the chart or EHR as one of the rea-
sons or diagnoses for the visit.
‡ The International Classification of Disease (9th and 10th Revisions) codes the diagnosis of substance “addiction” as substance
“dependence.”
§ A patient consuming one or more opioids with an ER/LA formulation receives 9 additional points regardless of the number of
different ER/LA products consumed.
# Include all prescription opioids consumed on a daily basis.
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instrument intended to provide healthcare professionals
with clinical decision support for assessing the most seri-
ous and important adverse effect that can occur in
patients being managed for pain using opioid therapy. It
provides current, quantitative, evidence-based informa-
tion about a patient’s level of risk of serious prescription
opioid-induced respiratory depression or overdose.
Risk Factors
The 15 items in RIOSORD include several factors well-
documented in the literature as predictors of fatal opioid
overdose. They comprise features of the prescription
opioid [4,47–52]; concomitant prescribed benzodiaze-
pines or antidepressants [1,53–56]; renal, liver, and pul-
monary comorbidities and active traumatic injury; and
mental health disorders including opioid dependence
[9,36,57,58]. In addition, increased health care utilization
in the form of a recent ED visit or hospitalization was
among the most significant predictors of experiencing
OSORD [59].
The total MED of the patient’s daily opioid regimen was
one of the variables most strongly associated with an
event, in a monotonic dose-response fashion beginning,
alarmingly, with an MED as low as 20 mg/day [14–17].
MED is one of the most consistently reported risk factors
for fatal overdose. Accurate, reliable calculation of the
patient’s total daily MED entails the use of standardized
morphine equivalent conversion factors. Numerous pub-
lished equianalgesic tables are available, but the opioid
conversion factors vary widely [40,60–64]. Therefore, to
maximize RIOSORD’s clinical utility and high predictive
performance, inclusion of MED in the risk index requires
use of a standardized automatic electronic calculator, as
currently available in a mobile, tablet, or Web-based plat-
form, to facilitate simple, rapid, accurate, and reliable
calculation.
Intended Use and Interpretation of Results
Pain is the most common reason patients seek medical
attention [65]. Approximately 80% of pain episodes
treated with opioids in the United States are short-term
[60,63]. However, an estimated 100 million to 116 million
U.S. adults have chronic pain [65,66]. The prescription of
opioids to manage chronic noncancer pain increased
dramatically since 2000 to approximately 9 million individ-
uals annually [5–7,9,67]. Managing acute, episodic, or
chronic pain with opioids is particularly challenging due to
the multidimensionality of pain and the multitude of influ-
ences affecting opioid efficacy and safety. RIOSORD,
which is based on a multivariable regression model, inte-
grates independent risk factors and adjusts for confound-
ing influences. As a result, RIOSORD can provide
valuable decision support to health care professionals to
manage pain more safely and effectively, particularly in
complex patients who are biologically vulnerable to seri-
ous opioid-related CNS or respiratory depression. RIO-
SORD supports but does not replace the health care
provider’s judgment in clinical decision-making.
RIOSORD is intended as a screening tool to be used by a
health care professional before prescribing opioids, to
assess a patient’s baseline risk of opioid-induced respira-
tory depression or overdose. It also can be employed
periodically during ongoing opioid treatment to re-
evaluate risk based on changes in a patient’s clinical con-
dition or medication regimen. Explaining the RIOSORD
score to a patient creates an opportunity to discuss the
benefits and risks associated with the use of opioids. It
also facilitates patient education regarding the word
Table 4 Risk classes and predicted probabilities
Risk Class
Risk Index
Score (Points)
All Patients
(n58,987),
n (%)
Overdose or Serious Opioid-Induced
Respiratory Depression (All patients,
n58,987)
Average Predicted
Probability (95% CI)
Observed
Incidence
1 0–24 7,133 (79.4) 0.03 (0.03, 0.03) 0.03
2 25–32 780 (8.7) 0.14 (0.14, 0.15) 0.14
3 33–37 306 (4.5) 0.24 (0.24, 0.24) 0.23
4 38–42 238 (2.7) 0.34 (0.34, 0.35) 0.37
5 43–46 133 (1.5) 0.46 (0.45, 0.46) 0.51
6 47–49 77 (0.9) 0.55 (0.54, 0.55) 0.55
7 50–54 101 (1.1) 0.64 (0.64, 0.65) 0.60
8 55–59 87 (1.0) 0.76 (0.75, 0.76) 0.79
9 60–66 73 (0.8) 0.85 (0.84, 0.85) 0.75
10 67 59 (0.7) 0.94 (0.93, 0.95) 0.86
Model performance
C-statistic5 0.88
Hosmer–Lemeshow goodness-of-fit statistic5 10.8 (P>0.05)
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overdose and the importance of adjusting modifiable risk
factors (e.g., adhering to prescribed treatment for comor-
bidities such as sleep apnea, or minimizing use of neuro-
depressive psychoactive substances and medications).
For example, the provider may begin a discussion with,
“Patients with risk scores similar to yours” (e.g., 50 points)
“were predicted to have an x% chance” (e.g., 76%) “of
experiencing a life-threatening opioid emergency such as
an overdose with slow or very shallow breathing and
unresponsiveness. This can occur under certain condi-
tions despite taking your opioid medication exactly as
prescribed. You can reduce your risk by. . .” (e.g., “using
your CPAP device for sleep apnea, following opioid dose
instructions, and not drinking alcohol”).
Patients identified as having increased risk are the most
likely to benefit from preventive and potentially life-
saving interventions. Options include patient and care-
giver education, increased attention when selecting an
opioid or increasing dose, consulting pain management
experts, possible pharmacogenetic testing, and height-
ened vigilance for serious opioid-related adverse effects
or the emergence of known risk factors. Naloxone, a
highly effective opioid antagonist, is recommended for
patients at increased risk for opioid overdose, including
those on chronic opioid therapy [68–75]. In 2014, the
U.S. Food and Drug Administration approved the first
naloxone product for use outside medically supervised
settings by family members or caregivers as a rescue
medication in the event of a known or suspected over-
dose as manifested by respiratory and/or CNS depres-
sion [73].
Strengths and Limitations
RIOSORD was developed using extensive administrative
health care data in the U.S. VHA population. Limitations
common in observational studies using administrative
data include limited or no information about : 1) poten-
tially relevant patient behavior, social characteristics,
and family history (such as familial substance use disor-
ders); 2) adherence to dosing instructions and actual
use of prescribed medication; 3) substances, medica-
tions, and treatment obtained outside VHA; and 4) ther-
apeutic indications for prescribed medications. As such,
the predictive ability of RIOSORD, like other tools
derived from observational data, is subject to residual
confounding by currently unknown or excluded contrib-
utory factors. Administrative data can be limited by
incompleteness, coding errors, and misclassification,
particularly for comorbidities including mental health and
substance use disorders. A gold standard administrative
(claims) code-based definition for the outcome of seri-
ous opioid-related respiratory/CNS depression or over-
dose does not exist currently, and the diagnostic
accuracy of our coding algorithm has not been validated
yet against linked patient medical records. In addition,
the VHA population includes relatively few women and
younger patients; the study sample might not accurately
reflect the broader U.S. population of medical users of
prescription opioids.
The risk factors selected as risk index items were chosen
partly because accurate, complete responses should be
readily identified by a health care professional in a
patient’s medical record in the context of a typical brief
provider-patient visit, or from medical and pharmacy
administrative (claims) data. The completion of RIOSORD
by a health care professional is intended to reduce
response gaps or errors that may decrease its predictive
accuracy and performance. This index does not include
all known risk factors, such as family history of substance
use disorders. In addition, some variables associated with
an event in the VHA sample were excluded, such as age,
race/ethnicity, and geographic location, because they dif-
fered from published findings from studies of fatal opioid-
related overdose in non-VHA populations. The limited
number of cases in the study sample and unknown exter-
nal generalizability of findings precluded stratifying the
analysis by the duration of opioid therapy or the acuity and
type of therapeutic indication (e.g., cancer-relatedness).
Implications for Future Research
While RIOSORD performed well in the VHA patient pop-
ulation, it should be assessed and further validated in a
separate population that is more representative of U.S.
medical users of prescription opioids. It also should be
evaluated in clinically defined subgroups of prescription
opioid users, based on characteristics of the pain condi-
tion (e.g., chronic vs acute and cancer vs noncancer).
RIOSORD will also benefit from prospective reliability
and validity testing across a broad spectrum of patients.
RIOSORD can be formatted for electronic administration
via Web or mobile platform to improve its real-world
deployment by enabling automated MED calculation,
risk scoring, and calculation of risk class.
Conclusion
RIOSORD is the first-known published risk index to pro-
vide current, evidence-based information to health care
providers regarding the risk of overdose or life-
threatening CNS/respiratory depression in medical users
of prescription opioids. Its performance should be fur-
ther assessed, and refined as necessary, in a larger,
more generalizable population, as well as prospectively.
Once validated, this index will assist health care profes-
sionals in identifying patients who are at increased risk
of serious opioid-induced respiratory depression or
overdose and help with decision-making regarding inter-
ventions to mitigate their risk.
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